

Faculty Disclosures Report - as of August 21, 2026

The COSTEM Congress seeks to balance the important benefits of physician-industry relationships with the potential risk that the financial goals of the industry may conflict with the professional goals of COSTEM participants. In doing so, the COSTEM Congress recognizes that it has a profound duty to its participants, the larger medical community and the public to ensure the integrity of all its scientific, educational, and advocacy activities and materials.

Educational Content Development

The COSTEM Congress requires all Program members and any others in a position to control the educational content to disclose any commercial financial interests prior to the development of the educational content. A process of resolution of conflict of interest is used for those members who do have financial interests related to the development of the content.

Presenters

The COSTEM Congress considers financial relationships to create actual conflicts of interest when presenters have both a financial relationship with a commercial interest and the opportunity to affect the policy of the COSTEM Congress of CME about the products or services of that commercial interest. The potential for Presenter to maintaining or increasing the value of the financial relationship with the commercial interest creates an incentive to influence the content of the CME – an incentive to insert commercial bias. All presenters of CME content should familiarize themselves with the policy of the COSTEM Congress of CME based on the CME providers of the Congress.

All COSTEM Faculty presenting CME are required to disclose the following prior to beginning their presentation:

- Any relevant financial relationships a CME presenter has had with manufacturers of commercial products or providers of commercial services within the past 12 months. The COSTEM Congress defines "relevant" financial relationships as those with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest
- CME presenters who report they have no known relevant financial relationships to disclose will declare "No Financial Relationships"

COSTEM Financial Disclosure Codes:

Type of affiliation / financial interest	Code
Honorarium	H
Receipt of consultation / advisory board / employment fees:	C
Other Financial or Material Support	F
Speaker's Bureau	S
Research funding	R
Employee	E
Nothing to declare: <i>Written as said statement</i>	
Other: <i>Written as stated on submitted form</i>	

Disclosure Information

Financial interest disclosures from program members and others in a position for control content:

Emanuele Angelucci, Italy

H Vertex, BMS
C Menarini Stemline, J&J, Pharmacosmos

Daniele Avenoso, Italy

C MEDAC, Sanofi, Therakos, Jazz Pharma
R MEDAC, Therakos

Andrea Bacigalupo, Italy

Nothing to declare

Michael Bishop, USA

Nothing to declare

Francesca Bonifazi, Italy

C Sanofi, Neovii, Novartis, Incyte

Yi-Bin Chen, USA

H Astellas

C Incyte, ImmunoFree, Ossium, ProTGen, Syndax, MaaT Pharma, Nestle, Novo Nordisk, Alexion, Daiichi Sankyo

Yael Cohen, Israel

C J&J, BMS, Gilead, Sanofi, Takeda, Pfizer, GSK

R J&J, Takeda

S GSK, J&J

Marcos de Lima, USA

Nothing to declare

Nihar Desai, Canada

Nothing to declare

Robin Foà, Italy

Nothing to declare

Nico Gagelmann, Germany

Nothing to declare

Eleni Gavriilaki, Greece

H,C Omeros, Astra Zeneca, SOBI

R Jazz Pharma, Kite

Francesca Gay, Italy

Nothing to declare

Hildegard Greinix, Austria

C,S Therakos, Sanofi, Neovii

R BMS

Carmelo Gurnari, Italy

Nothing to declare

Shernan Holtan, USA

C Sanofi, Origin CV

Christopher Hourigan, USA

C Astellas, BioRad, Syndax, Janssen

R Illumina

Other Ivivoscribe (travel support)

Xiaojun Huang, China

C Sanofi, BMS, Janssen

R Roche, MSD

Gloria Iacoboni, Spain

H AbbVie, Astra Zeneca, BMS, Kite/Gilead, Miltenyi, SOBI, Roche, Lilly

C Autolus, BMS, Kite/Gilead, Janssen, Miltenyi, AbbVie, MSD, Regeneron

Other AbbVie, Astra Zenea, Kite/Gilead, Miltenyi, Roche (travel support)

Nicolaus Kröger, Germany

H Therakos, Neovii, GSK

C Sanofi, Neovii, Alexion, Medac, Therakos

Franco Locatelli, Italy

H Miltenyi, Amgen, Novartis, BMS, Gilead, SOBI

C Amgen, Novartis, Sanofi, Vertex

Peihua (Peggy) Lu, China

Nothing to declare

Maximilian Merz, Germany

Nothing to declare

Lori Muffly, USA

H UptoDate

C Incyte, Autolus, Medexus, Merck

R Autolus, Kite, Imviva/Bioheng, Orca, Incyte

Arnon Nagler, Israel

Nothing to declare

Valentín Ortíz-Maldonado, Spain

H,C BMS, Pfizer

E Hospital Clínic de Barcelona

Zinaida Perić, Croatia

Nothing to declare

Alexander Perl, USA

Nothing to declare

Antonio Risitano, Italy

Nothing to declare

Marie Thérèse Rubio, France

Nothing to declare

Jaime Sanz Caballer, Spain

Nothing to declare

Michael Schmitt, Germany

Nothing to declare

Bart Lee Scott, USA

Nothing to declare

Bronwen Shaw, USA

C Therakos

Avichai Shimoni, Israel

Nothing to declare

Robert Soiffer, USA

C BMS

Other National Marrow Donor Program – Chair Emeritus

Pieter Sonneveld, Netherlands

C AbbVie, Amgen, Janssen, Pfizer, Sebia, BMS

R Amgen, BMS, Janssen, Regeneron

E Erasmus MC

Richard Stone, USA

Nothing to declare

Rainer Storb, USA

Nothing to declare

Marion Subklewe, Germany

H Boehringer Ingelheim, Gilead

C Amgen, Genmab, Janssen, Kite, Menarini Stemline, Molecular Partners, Novartis, AbbVie, AvenCell, BMS, Miltenyi, Pierre Fabre

R Amgen, AvenCell, BMS/Celgene, Miltenyi, Molecular Partners, Roche, Seagen

S Astra Zeneca, Gilead, LAWG

Other Gilead, Roche (travel support)

Felicitas Thol, Germany

C Daiichi Sankyo, AbbVie, BMS, Jazz Pharma

Magnus Tobiasson, Sweden

R BMS

Other Rarity – research collaboration

Sumithira Vasu, USA

Nothing to declare

Coen Veenstra, Netherlands

Nothing to declare